1st Quarter - Termination

ADAPTIVE BIOTECHNOLOGIES for ADAPTIVE BIOTECHNOLOGIES

Firm
Client
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Mar 23, 2022

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to T cells, COVID testing, pandemic preparedness and immune medicine H.R. 6102 and S. 3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions H.R. 5745, COVID-19 Access to Testing and Support for Immune Response Research Act of 2021 S. 3062 Departments of Labor, HHS, and Education, and Related Agencies Appropriations Act, FY2022

LobbyistCovered position, as disclosed
PAMELA LYNN BRADLEY covered legislative branch official

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3404 (117th), H.R. 5745 (117th), S. 3062 (117th), H.R. 6102 (117th)

Medicare/Medicaid MMM

H.R. 1946 and S. 1873- Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 H.R. 5745, COVID-19 Access to Testing and Support for Immune Response Research Act of 2021

LobbyistCovered position, as disclosed
PAMELA LYNN BRADLEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5745 (117th), S. 1873 (117th), H.R. 1946 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.